Role of RASSF1A promoter methylation in the pathogenesis of ovarian cancer: A meta-analysis

Genetic Testing and Molecular Biomarkers

Volumn 18, Issue 6, 2014, Pages 394-402

  Si, Jin Ge ^a   Su, Yuan Yuan ^a   Han, Yan Hua ^a   Chen, Ru Hong ^a  

^a People's Hospital of Zhongshan City   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PATIENT; CANCER TISSUE; DNA METHYLATION; ETHNICITY; HUMAN; ONCOGENE; OVARY CANCER; PATHOGENESIS; PROMOTER REGION; RASSF1A GENE; FEMALE; GENETICS; META ANALYSIS; OVARY TUMOR; PATHOLOGY;

RASSF1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

DNA METHYLATION; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84902011174     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2014.0022     Document Type: Article

References (35)

1. Bhagat R, Chadaga S, Premalata CS, et al. (2012) Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development. Cell Oncol (Dordr) 35:473-479
2. Bondurant AE, Huang Z, Whitaker RS, et al. (2011) Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer. Gynecol Oncol 123:581-587
3. Chen DL, Zhang J, Li L, et al. (2011) The relation between RASSF1A promoter CpG island methylation and RASSF1A protein expression in epithelial ovarian tumors. J Mod Oncol 19:1399-1402
4. Choi YL, Kang SY, Shin YK, et al. (2006) Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas. Virchows Arch 448:331-336. (Pubitemid 43357650
5. Del Re DP, Sadoshima J (2012) RASSF1A signaling in the heart: Novel functions beyond tumor suppression. Mol Biol Int 2012:154283
6. Donninger H, Vos MD, Clark GJ (2007) The RASSF1A tumor suppressor. J Cell Sci 120:3163-3172. (Pubitemid 350018407
7. Feng Q, Deftereos G, Hawes SE, et al. (2008) DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma. Gynecol Oncol 111:320-329
8. Fernandes MS, Carneiro F, Oliveira C, et al. (2013) Colorectal cancer and RASSF family - A special emphasis on RASSF1A. Int J Cancer 132:251-258
9. Fiolka R, Zubor P, Janusicova V, et al. (2013) Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer. Oncol Rep 30: 2878-2886
10. Gates MA, Rosner BA, Hecht JL, et al. (2010) Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 171:45-53
11. He Y, Jin MS, Du D, et al. (2011) Study on promoter methylation of RASSF 1A gene in ovarian cancer and peritoneal fluid. J Bengbu Med Col 36:35-37, 41
12. Helmbold P, Lahtz C, Herpel E, et al. (2009) Frequent hypermethylation of RASSF1A tumour suppressor gene promoter and presence of Merkel cell polyomavirus in small cell lung cancer. Eur J Cancer 45:2207-2211
13. Ibanez de Caceres I, Battagli C, Esteller M, et al. (2004) Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 64:6476-6481. (Pubitemid 39297903
14. Jervis S, Song H, Lee A, et al. (2014) Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. J Med Genet 51:108-113
15. Juhlin CC, Kiss NB, Villablanca A, et al. (2010) Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours. PLoS One 5:e9472
16. Karray-Chouayekh S, Trifa F, Khabir A, et al. (2010) Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients. J Cancer Res Clin Oncol 136:203-210
17. Kwa M, Muggia F (2013) Ovarian cancer: A brief historical overview of intraperitoneal trials. Ann Surg Oncol DOI: 10.1245/s10434-013-3219-8
18. Levesley J, Lusher ME, Lindsey JC, et al. (2011) RASSF1A and the BH3-only mimetic ABT-737 promote apoptosis in pediatric medulloblastoma cell lines. Neuro Oncol 13:1265-1276
19. Li QR, Liu PS, Feng JB (2008) Detection of aberrant methylation of RASSF1A gene in the tissue and the serum from ovarian tumor patients and its clinical significance. Chin J Cancer Prev Treat 15:374-377
20. Ma L, Zhang JH, Liu FR, et al. (2005) Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors. Chin J Oncol 27:657-659
21. Makarla PB, Saboorian MH, Ashfaq R, et al. (2005) Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 11:5365-5369. (Pubitemid 41060809
22. Malik K, Brown KW (2000) Epigenetic gene deregulation in cancer. Br J Cancer 83:1583-1588. (Pubitemid 32001697
23. Mitra S, Mazumder Indra D, Basu PS, et al. (2012) Alterations of RASSF1A in premalignant cervical lesions: Clinical and prognostic significance. Mol Carcinog 51:723-733
24. Montavon C, Gloss BS, Warton K, et al. (2012) Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol 124:582-588
25. Permuth-Wey J, Sellers TA (2009) Epidemiology of ovarian cancer. Methods Mol Biol 472:413-437
26. Peters JL, Sutton AJ, Jones DR, et al. (2006) Comparison of two methods to detect publication bias in meta-Analysis. JAMA 295:676-680. (Pubitemid 43209069
27. Shen WJ, Dai DQ, Guo KJ, et al. (2008) Promoter hypermethylation of RASSF1A,BRCA1 and p16 gene in epithelial ovarian cancer and its clinical significance. Chin J Cancer Prev Treat 15:530-533
28. Shi H, Li Y, Wang X, et al. (2013) Association between RASSF1A promoter methylation and ovarian cancer: A metaanalysis. PLoS One 8:e76787
29. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-Analyses. Eur J Epidemiol 25:603-605
30. Valdes R, Del Priore G (2010) Re: Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst 102:1599; author reply 1601
31. Wang LB (2013) Detection of RASSF1A gene aberrant methylation in the serum of epithelial ovarian tumor and its clinical significance. Matern Child Health Care Chin 28:2134-2136
32. Xie G, Hu C, Huang M (2011) Methylation status of RASSF1A and clinical efficacy of neoadjuvant therapy in patients with advanced epithelial ovarian cancer. J Cent South Univ (Med Sci) 36:631-633
33. Yee KS, Grochola L, Hamilton G, et al. (2012) A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma. Cancer Res 72:2206-2217
34. Yoon JH, Dammann R, Pfeifer GP (2001) Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer 94:212-217. (Pubitemid 32911415
35. Zintzaras E, Ioannidis JP (2005) HEGESMA: Genome search meta-Analysis and heterogeneity testing. Bioinformatics 21: 3672-3673. (Pubitemid 41264106.